Recent Posts

Senator Bernie Sanders is FDR’s unimaginative echo

That the Democrats’ two evenings of dueling oratory snippets are called “debates” validates Finley Peter Dunne’s prediction that “when we Americans are through with the English language, it will look as if it had been run over by a musical comedy.” Already a linguistic casualty of the campaign is the noun “socialism.” So, quickly, before Vermont Sen. Bernie Sanders’ campaign ...

Read More »

Central banks don’t need new tricks

The new central-banking toolkit looks a lot like the old one. European Central Bank (ECB) President Mario Draghi drew President Donald Trump’s ire after remarking that he’s prepared to act forcefully to combat slowing growth and receding inflation. What was remarkable about Draghi’s comments – beyond the fact that Trump even paid attention to them – is how undeterred he ...

Read More »

Pfizer’s cancer-drug deal takes pricey path to growth

Pfizer Inc. is demonstrating once again how expensive it is for pharma firms to buy their way to growth. The company announced that it’s paying almost $11 billion for cancer drugmaker Array Biopharma Inc. The deal would bolster Pfizer’s cancer portfolio and add medicines that could meaningfully augment sales and profit. But the company isn’t getting much of a bargain, ...

Read More »
Send this to a friend